β-tocotrienol | 153831-49-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: β-tocotrienol
• 英文别名: [R-(E,E)]-3,4-dihydro-2,5,8-trimethyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2H-1-benzopyran-6-ol；2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3,7,11-trienyl)-chroman-6-ol；2,5,8-trimethyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-chroman-6-ol；all-trans-ε-Tocopherol；2,5,8-trimethyl-2-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl]-3,4-dihydrochromen-6-ol
• CAS: 153831-49-3
• 化学式: C₂₈H₄₂O₂
• 分子量: 410.64
• InChiKey: FGYKUFVNYVMTAM-NTZRDTQNSA-N

物化性质

• 沸点：
  528.8±49.0 °C(Predicted)
• 密度：
  0.964±0.06 g/cm3(Predicted)
• 物理描述：
  Solid
• 熔点：
  <25°C

计算性质

• 辛醇/水分配系数(LogP)：
  8.9
• 重原子数：
  30
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  法尼基丙酮 在 四氢吡咯 、 lithium aluminium tetrahydride 、 三氯化铝 、 3 A molecular sieve 作用下， 以 乙醚 、 乙醇 为溶剂， 生成 β-tocotrienol
  参考文献：
  名称：

  Pearce; Parker; Deason, Journal of Medicinal Chemistry, 1994, vol. 37, # 4, p. 526 - 541

  摘要：

  DOI：

文献信息

• Treatment of mitochondrial diseases
  申请人：Walkinshaw Gail

  公开号：US20050065099A1

  公开（公告）日：2005-03-24

  The invention relates the method of treatment or amelioration of mitochondrial disorders such as Alzheimer's disease, Parkinson's disease, Friedreich's ataxia (FRDA), cerebellar ataxias, Leber's hereditary optic neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Myoclonic Epilepsy with Ragged Red Fibers (MERFF), amyotrophic lateral sclerosis (ALS), motor neuron diseases, Huntington's disease, macular degeneration, and epilepsy, with chroman derivatives of Formula I or Formula II as described herein.

  这项发明涉及治疗或改善线粒体疾病，如阿尔茨海默病、帕金森病、弗里德雷希共济失调症（FRDA）、小脑共济失调、勒伯遗传性视神经病变（LHON）、线粒体肌病、脑病、乳酸中毒、中风（MELAS）、带有红色纤维的肌阵挛性癫痫（MERFF）、肌萎缩侧索硬化症（ALS）、运动神经元疾病、亨廷顿病、黄斑变性和癫痫等疾病的治疗方法，所述方法使用本文描述的FormuLA I或FormuLA II的类胡萝卜素衍生物。
• [EN] TOCOTRIENOL DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN 5-LIPOXYGENASE RELATED DISEASES<br/>[FR] DÉRIVÉS DE TOCOTRIÉNOL, COMPOSITION PHARMACEUTIQUE ET LEUR MÉTHODE D'UTILISATION DANS LES MALADIES LIÉES À LA 5-LIPOXYGÉNASE
  申请人：UNIVERSITÉ D'ANGERS

  公开号：WO2017032881A1

  公开（公告）日：2017-03-02

  The present invention relates to compounds of formula (III) or to compounds of formula (IV) wherein R1, R2, R3 and R4 are as defined in the claims, and their use in therapeutic treatments of 5-lipoxygenase related diseases such as chronic airway inflammatory or dermatological disorders.

  本发明涉及公式（III）的化合物或公式（IV）的化合物，其中R1，R2，R3和R4如权利要求所定义，并且它们在治疗5-脂氧合酶相关疾病，如慢性气道炎症或皮肤病方面的用途。
• PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES
  申请人：EDISON PHARMACEUTICALS, INC.

  公开号：US20170037023A1

  公开（公告）日：2017-02-09

  The invention discloses novel processes for production, enrichment and/or isolation of alpha-tocotrienol from source material comprising at least one non-alpha-tocotrienol, such as natural extracts comprising mixed tocotrienols.

  该发明揭示了一种从源材料中生产、富集和/或分离α-生育酚三烯酚的新工艺，该源材料包括至少一种非α-生育酚三烯酚，例如包含混合生育酚三烯酚的天然提取物。
• Formulations of tocopherols and methods of making and using them
  申请人：——

  公开号：US20030022818A1

  公开（公告）日：2003-01-30

  Non-naturally-occuring compositions for use in amelioration of disruption of energy metabolism secondary to stress are described. The compositions comprise a tocopherol and/or a derivative thereof, and a synergist, and are particularly suited for use as nutritional supplements. Synergists include, but are not limited to, flavonoids and lactoferrin and/or derivatives thereof. Compositions comprising an optimized formulation comprising a tocopherol and an additional compound such as daidzein or biochanin A are also described. Methods of making these compositions and methods of ameliorating injury(ies) or disruption of energy metabolism secondary to stress, comprising administering such compositions, are also disclosed.

  本文描述了用于缓解由压力引起的能量代谢紊乱的非自然组合物。该组合物包括生育酚和/或其衍生物以及协同剂，并特别适用于用作营养补充剂。协同剂包括但不限于类黄酮和乳铁蛋白及/或其衍生物。本文还描述了包括生育酚和daidzein或biochanin A等额外化合物的优化配方的组合物。本文还公开了制备这些组合物的方法以及通过给予这些组合物来缓解由压力引起的损伤或能量代谢紊乱的方法。
• Formulations and methods for treatment or amelioration of inflammatory conditions
  申请人：Phinney Dodge Stephen

  公开号：US20050137253A1

  公开（公告）日：2005-06-23

  Formulations and methods for the treatment and/or amelioration of symptoms of inflammatory conditions and associated systemic inflammatory responses are described herein. The compositions comprise a non-alpha tocopherol (especially gamma-, beta-, or delta-tocopherol) and one or more of an omega-3 fatty acid, such as docosahexaenoic acid (DHA) or a flavonoid.

  本文描述了用于治疗和/或改善炎症状和相关全身炎症反应的配方和方法。这些组合物包括非α-生育酚（特别是γ-、β-或δ-生育酚）和一种或多种ω-3脂肪酸，例如二十二碳六烯酸（DHA）或类黄酮。